New hope for hard-to-treat breast cancer: experimental drug combo enters trials

NCT ID NCT07281976

Recruiting now Disease control Sponsor: Nanjing Leads Biolabs Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called LBL-024, either by itself or combined with chemotherapy (albumin-bound paclitaxel), in people whose triple negative breast cancer has come back or spread. The goal is to see if the drug can shrink tumors and control the disease. About 220 adults with this aggressive cancer type will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, 150081, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450000, China
Jiangsu Province Hospital
RECRUITING

Nanjing, Jiangsu, 210029, China
Liaoning Cancer Hospital
RECRUITING

Shenyang, Liaoning, 110000, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, 510120, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510062, China
The first hospital of Jilin University
RECRUITING

Changchun, Jilin, 130021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.